Effect of annual influenza vaccination on reducing lung cancer in patients with chronic obstructive pulmonary disease from a population-based cohort study

Kuan-Yuan Chen, MD∗,a,b, Sheng-Ming Wu, PhDb,c, Ju-Chi Liu, MD, PhDd,e, Kang-Yun Lee, MD, PhDab,c,∗

Abstract
Chronic obstructive pulmonary disease (COPD) patients are at a higher risk of development of lung cancer. Frequent exacerbations of COPD trigger the disease course to chronic inflammation which likely plays a role in the pathogenesis of lung cancer. Previous studies showed influenza virus infection is one of important causes for exacerbations of COPD. Therefore, the aim of this study was to know whether influenza vaccination could reduce the incidence of lung cancer in patients with COPD.

This cohort study enrolled patients (≥55 years old) with a recorded diagnosis of COPD between January 1, 2000 and December 31, 2012 by using the Taiwan Health Insurance Database. A propensity score was calculated to reduce vaccine therapy selection bias. Cox proportional hazard regressions were used to investigate the association between the influenza vaccination and lung cancer incidence after adjusting for known confounding factors. Besides, we categorized the patients into 4 groups according to vaccination status (unvaccinated, total number of vaccinations: 1, 2–3, ≥4) to evaluate the dose-dependent effect on reducing lung cancer occurrence of lung cancer in COPD patients.

Our study comprised of 28,752 eligible individuals from the COPD cohort database. Among them, 51% (14,630) received influenza vaccination; the rest (49%) of the COPD patients did not receive influenza vaccination. We observed that COPD patients receiving influenza vaccination had a lower risk of lung cancer (adjusted HR=0.40, 95% CI (0.35–0.45), P<.001). We also founded comparable protective effect in both sexes and all age groups (65–64, 65–74, ≥75) regardless of influenza seasonality. Furthermore, dose-dependent protective effect could be seen after stratifying patients according to the total number vaccinations, the adjusted HRs for lung cancer risk were 0.48 (0.40–0.54) and 0.24 (0.20–0.29) for patients who received 2 to 3 and ≥4 vaccinations during the follow-up period.

This population-based cohort study demonstrated that annual influenza vaccination administration could reduce incidence of lung cancer in COPD patients.

Abbreviations: CCI = Charlson Comorbidity Index, CI = confidence interval, COPD = Chronic obstructive pulmonary disease, DNA = deoxyribonucleic acid, HBV = hepatitis B, HPV = human papillomavirus, HR = hazard ratio, ICD-9-CM = The International Statistical Classification of Diseases and Related Health Problems 9th, clinical modification, ICS = inhaled corticosteroid, NAC = N-acetyl cysteine, NHI = National Health Insurance, NHIRD = National Health Insurance Research Database, PS = propensity scores, RNOS = reactive nitrogen and oxygen species, T1,1 = T helper 1, T1,2 = T helper 2.

Keywords: chronic obstructive pulmonary disease, frequent exacerbations, influenza vaccination, lung cancer

Editor: Jiaxun Ding.
KYC and SMW contributed equally to this study.

This work was supported by grants from the Ministry of Science and Technology of the Republic of China (MOST 105–2314-B-038–056-MY3), Ministry of Education of the Republic of China (DP2–107–21121-T04), Taipei Medical University and Shuang Ho Hospital (106TMU-SHH-18 and 107TMU-SHH-09) and Shuang Ho Hospital (107F RP-01–3).
The authors report no conflicts of interest.

∗Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei. °Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City. †Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei. ‡Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.

Correspondence: Ju-Chi Liu, Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan (e-mail: iliumcdv@tmu.edu.tw); Kang-Yun Lee, Taipei Medical University, Taipei, Taiwan, Province of China (e-mail: lee4949@ms41.hinet.net).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial Licence 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and build upon the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Chen KY, Wu SM, Liu JC, Lee KY. Effect of annual influenza vaccination on reducing lung cancer in patients with chronic obstructive pulmonary disease from a population-based cohort study. Medicine 2019;98:47(e18035).

Received: 8 April 2019 / Received in final form: 10 September 2019 / Accepted: 20 October 2019
http://dx.doi.org/10.1097/MD.0000000000018035
1. Introduction

Both chronic obstructive pulmonary disease (COPD) and lung cancer are major smoking-related diseases leading to morbidity and mortality worldwide.\cite{1} Epidemiological studies showed COPD was associated with an increase in risk of lung cancer.\cite{2,3} on the other hand, 50% to 70% lung cancer patients diagnosed with airflow obstruction evidence of COPD.\cite{4} Furthermore, a significant proportion of 33% patients with COPD died of lung cancer over a 14.5-year follow up.\cite{5} Currently, it remains unclear the exact mechanisms underlying the higher incidence of lung cancer in patients with COPD. However, progress of research findings on pathogenesis of linking there 2 diseases help to discover chemo-preventive or chemotherapeutic targets in recent years.

Un-resolving inflammation was a key shared pathogenesis of both COPD and lung cancer, and repeated or chronic airway infections was thought to be one important underlying mechanism. Exacerbations are characteristic of the clinical course of COPD with closely link to persistent amplifying inflammation. Virus infection is one of predominant causes for frequent exacerbations. Rhinoviruses are most common viruses related to exacerbations of COPD but influenza is more common in severe exacerbations necessary for admission.\cite{6} In view of lung cancer, main risk factors such as cigarette smoking, environmental pollution, radiation, and exposure to asbestos have been implicated and virus like human papillomavirus (HPV) represents an additional one.\cite{7} HPV vaccine is reasonable to be introduced to reduce incidence of HPV cervical and other HPV-related cancers including lung cancer but only effective in cervical cancer prevention reported currently.\cite{8}

Considering lung cancer occurred in COPD patients, possibly frequent exacerbations resulted from repeated or chronic viruses infections drove carcinogenesis of lung, we addressed the question whether available influenza vaccination could reduce lung cancer incidence in COPD patients. To clarify the potential protective benefit of influenza vaccination on occurrence of lung cancer in Taiwanese patients with COPD, we performed a population-based cohort study using reimbursement claims from Taiwan’s National Health Insurance Research Database (NHIRD).

2. Materials and methods

The National Health Insurance (NHI) program has been established since 1995 to provide comprehensive health insurance consist of all of Taiwan residents. Nowadays, 98% of the more than 23 million people are covered under the NHI. We analyzed information obtained from the Taiwan NHIRD 2001 to 2012. There were no statistically significant differences in age, sex, or healthcare costs between the sample group and all enrollees. Influenza season was defined as the interval during October to March according to Taiwan Center of Disease Control. The study was approved by the Joint Institutional Review Board of Taipei Medical University (approval no. N201708051).

This study screens all patients who visited healthcare facilities in Taiwan with diagnosis of COPD (International Classification of Disease, the 9th Revision, Clinical Modification Code) over a 12-year period (n=116,107) from January 1, 2000 to December 31, 2012. Patients without subsequent COPD visit within one year were excluded (n=45009) due to be considered no chronic pulmonary disease (Fig. 1). We also excluded 39,053 patients as following criteria:

![Figure 1. The process of patient selection from a representative database from National Health Research Institute of Taiwan 1,000,000 subjects from year 2001 to 2012 registry of all NHI database for inclusion. COPD=chronic obstructive pulmonary disease.](image-url)

Patients with any inpatient or outpatient diagnosis related to cancer before the date of cohort enter (n=4407).

Individuals had already any vaccinated within 6 months before the date of cohort enter (n=3254) and

Patients with age <55 years old (n=31,392).

The indication of receiving administration of influenza vaccination in Taiwan are those high-risk elderly population (people aged ≥50 with type 2 diabetes, chronic liver infection of liver cirrhosis, cardiovascular diseases, or chronic pulmonary disease) since 1998, and for all adults older than 65 years since 2001.\cite{9} The vaccination status was recognized by code V048 and/or the use of vaccine (confirmed by drug codes). Each patient was reviewed for the Charlson Comorbidity Index (CCI) and risk factors for CAD (the main co-morbidity of COPD): hypertension, diabetes mellitus, dyslipidemia and associated medications: statins, metformin, and aspirin. The primary endpoints of our study were incidence of lung cancer (ICD-9-CM codes 162.X) in COPD patients during the influenza season, non-influenza season (April-September), and all seasons during the follow-up years.

2.1. Statistical analysis

A propensity scores (PS) are used to reduce selection bias and estimate effect of vaccination by accounting for the covariates that predict receiving the intervention (vaccine) with a logistic regression model.\cite{10} Categorical variables were compared using chi-square test and continuous variables using t test. The hazard ratio (HR) and 95% confidence interval (CI) for the association between the influenza vaccination and the occurrence of lung
cancer in COPD patients was analyzed by Cox proportional hazards regression analysis. The association between the seasonal effect of vaccination and incidence of lung cancer was also examined. To study the dose-effect of influenza vaccinations on incidence of lung cancer, we categorized the patients into four groups by vaccination status (unvaccinated, total number of vaccinations: 1, 2 to 3, and ≥4). These data were stratified according to the patients’ age, sex, comorbidity, and associated medication use. Sensitivity analyses were applied to evaluate the difference and consistency between the influenza vaccination use and the risk of lung cancer in COPD patients. This study performed all statistical analyses using SPSS 19.0 and SAS 9.2 software. The significance criterion was set at \( P < .05 \).

### 3. Results

Totally, 28,752 eligible individuals were enrolled into the COPD cohort. Of the study population, 51% (14,630) received influenza vaccination; the rest (49%) of the COPD patients did not receive influenza vaccination (Table 1). There was a significant difference \( (P < .001) \) between the two groups including distributions of age, level of urbanization, and monthly income (Table 1). Table 1 also showed prevalence of certain preexisting medical comorbidities, including CCI \( (P < .001) \), diabetes \( (P = .005) \), hypertension \( (P < .001) \) and dyslipidemia \( (P < .001) \) was higher in the unvaccinated than vaccinated group. In addition, the unvaccinated group demonstrated higher percentage of

| Characteristic of the COPD cohort study patients. |
|-----------------------------------------------|
| Whole cohort \((n = 28,752)\) | Unvaccinated \((n = 14,122)\) | Vaccinated \((n = 14,630)\) |
| --- | --- | --- |
| **Age, years (Mean ± SD)** | 69.62 (9.26) | 67.91 (10.20) | 71.27 (7.89) |
| 55–64 | 10,463 (36.39) | 6927 (40.05) | 3356 (24.17) |
| 65–74 | 9899 (34.43) | 3485 (24.75) | 6404 (43.77) |
| ≥75 | 8390 (29.18) | 3700 (24.75) | 4690 (32.06) |
| **Gender** | | | |
| Female | 12,741 (44.31) | 6247 (44.24) | 6494 (44.39) |
| Male | 16,011 (55.69) | 7875 (55.76) | 8136 (55.61) |
| **CCI Index** | | | |
| 0 | 6074 (21.13) | 2879 (20.39) | 3195 (21.84) |
| 1 | 7722 (26.86) | 3674 (26.02) | 4048 (27.67) |
| 2 | 6222 (21.64) | 3081 (21.82) | 3141 (21.47) |
| ≥3 | 8734 (30.38) | 4488 (31.78) | 4246 (29.02) |
| **Diabetes** | | | |
| No | 20,141 (70.05) | 9784 (69.28) | 10357 (70.79) |
| Yes | 8611 (29.95) | 4338 (30.72) | 4273 (29.21) |
| **Hypertension** | | | |
| No | 10,939 (38.05) | 5362 (39.88) | 5307 (36.27) |
| Yes | 17,813 (61.95) | 8490 (60.12) | 9323 (63.73) |
| **Dyslipidemia** | | | |
| No | 18,921 (65.81) | 9302 (63.96) | 9889 (67.59) |
| Yes | 9831 (34.19) | 5090 (36.04) | 4741 (32.41) |
| **Statin** | | | |
| <28 d | 20,452 (71.13) | 10,652 (75.43) | 9830 (66.99) |
| 28–365 d | 4067 (14.15) | 1783 (12.63) | 2284 (15.61) |
| >365 d | 4233 (14.72) | 1687 (11.95) | 2546 (17.40) |
| **Metformin** | | | |
| <28 d | 22,513 (78.30) | 11,350 (80.37) | 11163 (76.30) |
| 28–365 d | 2116 (7.36) | 1080 (7.65) | 1036 (7.08) |
| >365 d | 4123 (14.34) | 1692 (11.98) | 2431 (16.62) |
| **Aspirin** | | | |
| <28 d | 16,037 (55.78) | 9259 (65.56) | 6778 (46.33) |
| 28–365 d | 5824 (20.26) | 2503 (17.72) | 3221 (22.70) |
| >365 d | 6891 (23.97) | 2260 (16.71) | 4531 (30.97) |
| **Level of urbanization** | | | |
| Urban | 19,100 (66.46) | 10031 (71.03) | 9079 (62.06) |
| Suburban | 6297 (21.90) | 2801 (19.83) | 3496 (23.90) |
| Rural | 3345 (11.63) | 1290 (9.13) | 2055 (14.05) |
| **Monthly income (NT$)** | | | |
| 0 | 3066 (10.66) | 1239 (9.41) | 1737 (11.87) |
| 1–21,000 | 7378 (25.66) | 3106 (21.99) | 4272 (29.20) |
| 21,000–33,300 | 10,680 (37.15) | 4809 (34.05) | 5871 (40.13) |
| ≥33,301 | 7628 (26.53) | 4878 (34.54) | 2750 (18.80) |

*CO**PD* = chronic obstructive pulmonary disease, SD = Standard Deviation.

*Comparison between Unvaccinated and Vaccinated.

†CCI Index: Charlson Comorbidity Index.
comorbidities-associated medication use including metformin (P < .001), statin (P < .001) and aspirin (P < .001) than in vaccinated group did.

The incidence of the lung cancer was significantly lower in the influenza vaccinated group after we adjusted for potential confounders (adjusted HR 0.40, 95% CI 0.35–0.45 P < .001) than in the unvaccinated group (Table 2). The similar protective effects were also observed in both sexes and all elderly-age groups (55–64 years, 65–74 years, and 75 years and older) irrespective of influenza seasonality (Table 2).

### 3.1. Sensitivity analysis

The sensitivity analysis adjustments had an effect on evaluation of the association of influenza vaccination use with risk of lung cancer in different models. Table 3 demonstrates that the protective effects in the influenza vaccinated patients when stratified according to the total number of vaccinations in the main model and remained significant effect in subgroup analysis. Interestingly, dose-dependent protective effect can be seen when patients received influenza vaccination more than two doses (Table 3). The adjusted HRs for lung cancer risk were 0.48 (0.40–0.54) and 0.24 (0.20–0.29) for patients who received 2 to 3 and ≥4 vaccinations during the follow-up period.

### 4. Discussion

We observed that patients with COPD who had received influenza vaccination could reduce risk of lung cancer in this population-based cohort study. In our study, the mean age of patients received influenza vaccination was older than unvaccinated group and significant difference in comorbidity with related medications between the 2 groups was found. These different factors could influence the risk of lung cancer development in general patients including age, statin and metformin use. COPD patients are at increased risk for development of primary lung cancer,[11] particularly for squamous cell carcinoma.[12] The association between COPD and lung cancer is attributed from shared smoking exposure and subsequent airflow limitation,[13] whereas some studies demonstrated the risk of both diseases independent of patient age or extent of tobacco use.[14] The possible mechanisms in connection of COPD and lung cancer are oxidative stress and chronic inflammation.[14] The first, the most common cause of COPD is cigarettes smoking which introduce particulates and oxidant including reactive nitrogen and oxygen species (RNOS)[15] into airways and lung parenchyma. The RNOS subsequently resulted in oxidative stress and injury of epithelial cells lining on airways and alveolar walls.
The oxidative stress induced the accumulation of cell injury by DNA damage, lipid peroxidation, oxidation of amino acids, and oxidation of inorganic enzyme co-factors. In addition, unbalanced oxidant-induced deoxyribonucleic acid (DNA) damage and repair in COPD triggered to develop lung cancer, involving cancer initiation and progression.

Second, COPD is characterized by chronic inflammation of lower airways, which macrophages, neutrophils, and lymphocytes are main immune cells orchestrated and amplified the inflammation in the progression of disease. The propagation and the maintenance of inflammation increased risk of cancer development was reported in the literature, but the link between chronic low airways inflammation to lung cancer is still not fully elucidated. Different phenotype of immune cells infiltration in the lung were found between COPD and lung cancer. Macrophages, T helper 1 (Th1) or cytotoxic profile are predominant inflammatory cells in COPD; however, most solid tumors polarize immune cells towards a M2 macrophages and T helper 2 (Th2) lymphocytes. The time-varying on phenotype of immune cells profile in COPD lead to lung cancer development. These changes may be attributed from that oxidative stress in COPD patients provide genotoxicity for DNA adduct formation with subsequent genetic mutation which triggers early stage neoplasm forming and secreting cytokines and

### Table 3
Sensitivity analysis of adjusted HRs of vaccination in risk reduction of lung cancer.

|                       | Unvaccinated | Vaccinated |  |  |  | P value for trend |
|-----------------------|--------------|------------|---|---|---|------------------|
|                       | Adjust HR (95% C.I.) | Adjust HR (95% C.I.) | Adjust HR (95% C.I.) | Adjust HR (95% C.I.) |  |
| Main model*2           | 1.00         | 0.65 (0.55, 0.77)** | 0.48 (0.40, 0.54)** | 0.24 (0.20, 0.29)** | <.001 |
| Additional covariates*1|  |  |  |  |  |
| Main model + statin    | 1.00         | 0.66 (0.56, 0.79)** | 0.48 (0.40, 0.56)** | 0.24 (0.20, 0.29)** | <.001 |
| Main model + metformin | 1.00         | 0.65 (0.55, 0.77)** | 0.46 (0.39, 0.56)** | 0.23 (0.19, 0.28)** | <.001 |
| Main model + RAA       | 1.00         | 0.69 (0.59, 0.82)** | 0.51 (0.43, 0.66)** | 0.26 (0.21, 0.32)** | <.001 |
| Main model + aspirin   | 1.00         | 0.69 (0.58, 0.81)** | 0.50 (0.42, 0.59)** | 0.25 (0.21, 0.31)** | <.001 |

| Subgroup effects      |  |  |  |  |  |
| Age                   |  |  |  |  |  |
| 55–64                 | 1.00         | 0.51 (0.34, 0.75)** | 0.40 (0.27, 0.60)** | 0.21 (0.12, 0.39)** | <.001 |
| 65–74                 | 1.00         | 0.76 (0.59, 0.97)** | 0.46 (0.36, 0.66)** | 0.21 (0.16, 0.28)** | <.001 |
| 75+                   | 1.00         | 0.58 (0.44, 0.77)** | 0.44 (0.34, 0.58)** | 0.23 (0.17, 0.32)** | <.001 |
| Sex                   |  |  |  |  |  |
| Female                | 1.00         | 0.74 (0.55, 1.00)  | 0.53 (0.40, 0.72)** | 0.21 (0.14, 0.31)** | <.001 |
| Male                  | 1.00         | 0.61 (0.50, 0.75)** | 0.42 (0.34, 0.51)** | 0.22 (0.17, 0.27)** | <.001 |
| CCI Index*2           |  |  |  |  |  |
| 0                     | 1.00         | 0.57 (0.40, 0.80)** | 0.41 (0.30, 0.58)** | 0.18 (0.12, 0.27)** | <.001 |
| 1                     | 1.00         | 0.64 (0.46, 0.88)** | 0.58 (0.43, 0.78)** | 0.24 (0.17, 0.33)** | <.001 |
| 2                     | 1.00         | 0.68 (0.48, 0.96)** | 0.46 (0.32, 0.66)** | 0.19 (0.12, 0.30)** | <.001 |
| 3                     | 1.00         | 0.72 (0.52, 1.01)  | 0.35 (0.24, 0.52)** | 0.28 (0.19, 0.41)** | <.001 |
| Diabetes              |  |  |  |  |  |
| No                    | 1.00         | 0.68 (0.56, 0.83)** | 0.46 (0.38, 0.56)** | 0.23 (0.19, 0.29)** | <.001 |
| Yes                   | 1.00         | 0.57 (0.40, 0.80)** | 0.42 (0.32, 0.62)** | 0.20 (0.13, 0.30)** | <.001 |
| Dyslipidemia          |  |  |  |  |  |
| No                    | 1.00         | 0.68 (0.56, 0.83)** | 0.48 (0.39, 0.58)** | 0.25 (0.20, 0.31)** | <.001 |
| Yes                   | 1.00         | 0.58 (0.42, 0.80)** | 0.42 (0.30, 0.57)** | 0.15 (0.10, 0.23)** | <.001 |
| Hypertension          |  |  |  |  |  |
| No                    | 1.00         | 0.57 (0.44, 0.74)** | 0.46 (0.36, 0.59)** | 0.19 (0.14, 0.26)** | <.001 |
| Yes                   | 1.00         | 0.72 (0.58, 0.90)** | 0.46 (0.37, 0.58)** | 0.25 (0.19, 0.32)** | <.001 |
| Statin                |  |  |  |  |  |
| <28 d                 | 1.00         | 0.63 (0.52, 0.76)** | 0.42 (0.35, 0.51)** | 0.23 (0.19, 0.29)** | <.001 |
| 28–365 d              | 1.00         | 1.08 (0.65, 1.79)  | 0.69 (0.42, 1.14)  | 0.31 (0.17, 0.56)** | <.001 |
| >365 d                | 1.00         | 0.68 (0.31, 1.52)  | 1.21 (0.68, 2.16)  | 0.35 (0.18, 0.69)** | .013 |
| Metformin             |  |  |  |  |  |
| <28 d                 | 1.00         | 0.66 (0.55, 0.76)** | 0.43 (0.36, 0.52)** | 0.20 (0.16, 0.29)** | <.001 |
| 28–365 d              | 1.00         | 0.72 (0.35, 1.47)  | 0.58 (0.29, 1.17)  | 0.45 (0.23, 0.92)** | .019 |
| >365 d                | 1.00         | 0.61 (0.30, 1.24)  | 0.90 (0.52, 1.54)  | 0.40 (0.22, 0.72)** | .008 |
| Aspirin               |  |  |  |  |  |
| <28 d                 | 1.00         | 0.69 (0.56, 0.86)** | 0.43 (0.34, 0.53)** | 0.22 (0.16, 0.28)** | <.001 |
| 28–365 d              | 1.00         | 0.69 (0.47, 1.01)  | 0.53 (0.37, 0.70)** | 0.30 (0.20, 0.48)** | <.001 |
| >365 d                | 1.00         | 0.95 (0.58, 1.57)  | 1.03 (0.68, 1.56)  | 0.44 (0.28, 0.69)** | .001 |

HR = hazard ratio.
*P < .05.
**P < .01.
*** P < .001.
1 CCI index: Charlson Comorbidity Index.
2 Main model is adjusted for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipemia, level of urbanization, Monthly income in propensity score.
3 The models were adjusted for covariates in the main model as well as each additional listed covariate.
chemokines that skew the immune cell profiles in favor of tumor promotion.[27]

Exploring possible pathogenesis of linking COPD to lung cancer mentioned above, we could provide specific strategies for COPD patients to reduce risk of lung cancer. Chronic antioxidant therapy, for example N-acetyl cysteine (NAC) may be benefit of reducing exacerbations of COPD and lung cancer incidence based of mitigating oxidative stress in both diseases but the results from trials of NAC treatment in COPD showed small reduction in acute exacerbations,[28] furthermore, use of antioxidants in mice increased cancer risk in COPD model.[29] Given shared mechanism of chronic inflammation in both diseases, long-term treatment with anti-inflammatory agent of inhaled corticosteroid (ICS) in COPD was performed but the results showed controversial in survival benefit of lung cancer.[30,31] Changes over time of lipid metabolism in cancers including lung cancer has been investigated before but the protective effect of statin administering was not clearly demonstrated by those studies.[32,33]

Vaccination in preventing cancer has been made significant progress particularly in hepatocellular carcinoma with hepatitis B (HBV) vaccine and HPV-related cervical and other cancers with HPV vaccines.[34] Not any research has been reported before about vaccination in lung cancer prevention. This is the first population-based cohort study to show influenza vaccination could reduce lung cancer in COPD patients. The possible explanation for the promising result may be decreasing frequency of exacerbations in patients of COPD caused influenza virus infection with resultant persistence of inflammation. Another possible reason is annual influenza vaccination administering may trigger Th1 immune response to augment anti-tumor defense. In addition, the dose-dependent effect showed in our study implicated the boosted and consolidated anti-tumor immunity after repeated receiving influenza vaccination.

Our group analyzed the associated of influenza vaccination in COPD with the reduction of hospitalization for acute coronary syndrome from the same database,[35] which suggested the protective effect of influenza vaccination on endothelial cells of COPD patients. In this study, we showed the influence of influenza vaccination on reduction of lung cancer in COPD, which may implied the similar protective role on epithelial cells of lung in patients. However, some limitations of this study should be addressed. First, several confounding factors relevant to cancers, including smoking, alcohol intake, and other over-the-counter drug use, body mass index, were not contained in our database. Second, the diagnoses of COPD and the vaccination status in our study were according to ICD-9 codes or drug codes, thus the diagnostic accuracy of the database may be a problem. Finally, we presumed all prescribed medications associated with anti-cancers such as statin and metformin were actually taken by patients to mitigate the effect of noncompliance to influence our result.

5. Conclusion

In conclusion, this study is the first article to demonstrate the protective effect of influenza vaccination against lung cancer in COPD patients. Furthermore, this study showed dose-dependent effect in reducing the incidence of lung cancer. In the future, there is need for prospective large clinical trials and elucidation underlying mechanisms in basis of this study.

Author contributions

Conceptualization: Kuan-Yuan Chen.

Formal analysis: Sheng-Ming Wu.

Investigation: Sheng-Ming Wu.

Supervision: Sheng-Ming Wu, Ju-Chi Liu, Kang-Yun Lee.

Writing – original draft: Kuan-Yuan Chen.

Writing – review & editing: Ju-Chi Liu, Kang-Yun Lee.

Kang-Yun Lee orcid: 0000-0003-4705-5802.

References

[1] Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.

[2] Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987;106:512–8.

[3] Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009;34:380–6.

[4] Yao H, Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 2009;9:375–83.

[5] Anthonisen NR, Skews MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233–9.

[6] Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355–65.

[7] Klein F, Amin Koth WF, Petersen I. Incidence of human papilloma virus in lung cancer. Lung Cancer 2009;65:13–8.

[8] Kane MA, Sherris J, Courser P, et al. Chapter 15: HPV vaccine use in the developing world. Vaccine 2006;24(Suppl 3): S3/132–139.

[9] Wang CS, Wang ST, Lai CT, et al. Impact of influenza vaccination on major cause-specific mortality. Vaccine 2007;25:1196–203.

[10] D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–81.

[11] Skillrud DM, Olford KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986;105:503–7.

[12] Papic A, Casoni G, Caramori G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004;59:679–81.

[13] Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005;23:3175–85.

[14] Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011;81:265–84.

[15] Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer 2015;90:121–7.

[16] Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010;31:37–49.

[17] Fischer BM, Pavlikso E, Vojnovic JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011;6:413–21.

[18] Caramori G, Adcock IM, Casolari P, et al. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax 2011;66:521–7.

[19] Kryston TB, Georgiev AB, Posis P, et al. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011;713:193–201.

[20] Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 1997;105(Suppl 4):873–82.

[21] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45.

[22] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45.

[23] Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 2010;87:401–6.

[24] Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung carcinogenesis: implications for inflammation in lung cancer. Ann Intern Med 2005;142:233–9.

[25] Kryston TB, Georgiev AB, Posis P, et al. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011;713:193–201.

[26] Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 1997;105(Suppl 4):873–82.

[27] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45.

[28] Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 2010;87:401–6.

[29] Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung carcinogenesis: implications for inflammation in lung cancer. Ann Intern Med 2005;142:233–9.

[30] Kryston TB, Georgiev AB, Posis P, et al. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011;713:193–201.

[31] Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 1997;105(Suppl 4):873–82.
[26] Haqqani AS, Sandhu JK, Birnboim HC. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutant tumors. Neoplasia 2000;2:561-8.

[27] Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 2006;25:307-13.

[28] Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015:CD001287.

[29] Sayin VI, Ibrahim MX, Larsson E, et al. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014;6:221ra215.

[30] Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–89.

[31] Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:712–9.

[32] Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74–80.

[33] Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012;279:2610–23.

[34] Kane MA. Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res (Phila) 2012;5:24–9.

[35] Sung LC, Chen CI, Fang YA, et al. Influenza vaccination reduces hospitalization for acute coronary syndrome in elderly patients with chronic obstructive pulmonary disease: a population-based cohort study. Vaccine 2014;32:3843–9.